Nostrapharmus predicts that a more strategic and proactive approach to safety will win back consumer confidence
Drug safety in pharma is under extreme pressure right now. Trusted blue chip organisations have been publicly accused of putting profits ahead of patient safety, and negative stories in the media are fuelling public and stakeholder anxiety. Legislators and regulators are feeling twitchy, and are demanding proof from all pharma companies that their teams are building safety risk management into everything they do. The overall result is severe demand on the industry to prove that patient safety forms the nucleus of all work carried out whilst developing a drug from conception to clinical and through to manufacturing and marketing. This means that pharma’s drug safety units are being asked to take a much wider, more strategic look at a drug’s safety profile, starting as early as possible in a product’s life cycle.
This change is not just a tweak to the current ways of working, it is a huge transformation in terms of today’s readily used processes and teams’ mind-sets; and it will require big commitment and determination from the pharma companies to see it through.
To read the article in full, please click on the pdf link below:
or to read the magazine, please click on the link below, the article can be found on pages 57-58
About Pharma Magazine
Aimed at the international pharmaceutical and bio-pharmaceutical community, Pharma magazine covers every aspect of manufacturing from R&D to finished product. With a worldwide circulation of more than 40,000 individuals, it is the first truly global magazine for the pharma industry, bringing together the disciplines of discovery and development, the drug manufacturing process and the resultant business and management issues. For further information visit the Pharma website at www.pharma-mag.com